Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$0.32
-$0.17(-11.18%)
At close: 4:00 PM EST
$0.32
-$0.17(-11.18%)
Day’s Range― - ―
52-Week Range$4.14 - $75.50
Previous CloseN/A
Volume2.03M
Average Volume (3M)557.82K
Market Cap
$33.67M
Enterprise Value$36.05M
Total Cash (Recent Filing)$692.30K
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta1.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,187,505
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-248.89
Enterprise Value/Ebitda-1.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic M&A PipelinePursuing acquisitions to build a healthcare services arm is a structural strategy to convert a research-stage biotech into a revenue-generating, diversified enterprise. If closed, these deals could materially reduce reliance on financing, add predictable revenue streams, and improve long-term cash flow dynamics, though outcomes remain contingent on due diligence and closing.
Lower Debt LevelsA materially reduced debt load versus prior years improves financial flexibility and lowers interest obligations, which extends runway for R&D and potential integration of acquisitions. This durable improvement in capital structure lessens short-term refinancing pressure and gives management more options to fund strategic priorities.
Listing Continuity PreservedRestoring Nasdaq bid-price compliance preserves the company's listing on the Nasdaq Global Market, maintaining access to a deep investor base and regulated capital markets. Continued listing supports longer-term financing capability, credibility with partners, and smoother execution of strategic transactions compared with facing immediate delisting.
Bears Say
No Revenue; Cash BurnSustained zero revenue and roughly $12M trailing twelve‑month free cash outflow indicate the company remains heavily dependent on external capital. This structural cash burn constrains the pace of clinical and commercial development, increases dilution risk from future financings, and can limit strategic optionality if acquisition deals fail to close.
Negative Equity / Solvency RiskPersistently negative shareholders' equity signals a fragile balance sheet that complicates borrowing, raises counterparty concerns, and distorts leverage metrics. Over the medium term this condition can increase the cost of capital, reduce partner and vendor confidence, and heighten the risk that management must pursue dilutive financing or asset sales to remain solvent.
Market-value Listing RiskAn active Nasdaq market-value deficiency is a structural governance and market access risk. If unresolved by the Oct 2026 deadlines the company may need to transfer listings or take remedial actions, which can impair investor confidence, reduce liquidity, and complicate future capital raises or strategic transactions over the coming months.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $4.13 and its highest was $75.50 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $33.67M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tevogen Bio Holdings’s earnings last quarter?
Currently, no data Available
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 4,187,505 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Sold Shares
Worth $6.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.8%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
241.39%
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
TVGN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―